$RLFTF (related) DD by El Huron on Ya-h00 - I wen
Post# of 653
(Total Views: 246)
Posted On: 04/05/2021 7:39:00 AM
$RLFTF (related) DD by El Huron on Ya-h00 - I went through the S-4 merger file from NRX again the other day.
Found there again very interesting puzzle pieces!
regarding the supply chain:
Bachem was contracted to produce and supply 1KG Aviptadil for 1Q/2021!
In addition, one has also at the Polypeptide Group Inc. (Bachem competitor!) for production from 2Q2021 (p. 191)!
Then I found references to the Stockpile Dimension. DOD requires NRX to be able to secure 100,000 treatments per quarter (p. 241). Further, NRX writes that with the above orders, they have enough aviptadil for the next 2 years (100,000 treatments/quarter) (p. 191)
Cardinal Health has been selected as the exclusive US distributor (p. F-62).
Guys I think they have a lot more going on in the background than we imagine and know. I think we are all in for a great 2021!
reply from Hans: Thanks for the passing on this info. I know a lot of people get frustrated by the so-called lack of pr.
I suspect many these people who want a lot of pr on what's going on behind the scenes to pump up the stock price are the first ones to cry "foul" and "lawsuit" if things don't work out.
There is so much that needs to be in place before EUA (inventory, manufacturing capacity, distribution channels....etc) people that have done their DD know the potential of what they own in RFL - but there is still no guarantee until EUA - but a lot of that risk got reduced with the result of the trial.
There is a lot of experience working on getting Zyesami to market. Our day will come....hang on to your shares. GLA
Found there again very interesting puzzle pieces!
regarding the supply chain:
Bachem was contracted to produce and supply 1KG Aviptadil for 1Q/2021!
In addition, one has also at the Polypeptide Group Inc. (Bachem competitor!) for production from 2Q2021 (p. 191)!
Then I found references to the Stockpile Dimension. DOD requires NRX to be able to secure 100,000 treatments per quarter (p. 241). Further, NRX writes that with the above orders, they have enough aviptadil for the next 2 years (100,000 treatments/quarter) (p. 191)
Cardinal Health has been selected as the exclusive US distributor (p. F-62).
Guys I think they have a lot more going on in the background than we imagine and know. I think we are all in for a great 2021!
reply from Hans: Thanks for the passing on this info. I know a lot of people get frustrated by the so-called lack of pr.
I suspect many these people who want a lot of pr on what's going on behind the scenes to pump up the stock price are the first ones to cry "foul" and "lawsuit" if things don't work out.
There is so much that needs to be in place before EUA (inventory, manufacturing capacity, distribution channels....etc) people that have done their DD know the potential of what they own in RFL - but there is still no guarantee until EUA - but a lot of that risk got reduced with the result of the trial.
There is a lot of experience working on getting Zyesami to market. Our day will come....hang on to your shares. GLA
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ